PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30880686-2 2019 The transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), a key EMT activator, has recently been related to docetaxel resistance, the main chemotherapeutic used in advanced prostate cancer treatment. Docetaxel 120-129 zinc finger E-box binding homeobox 1 Homo sapiens 25-61 34175815-6 2021 Upstream mediators of EMT such as ZEB1/2, TGF-beta, microRNAs, and so on are involved in regulating response of cancer cells to PTX and DTX. Docetaxel 136-139 zinc finger E-box binding homeobox 1 Homo sapiens 34-40 30880686-2 2019 The transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), a key EMT activator, has recently been related to docetaxel resistance, the main chemotherapeutic used in advanced prostate cancer treatment. Docetaxel 120-129 zinc finger E-box binding homeobox 1 Homo sapiens 63-67 30880686-5 2019 In this work, we used prostate cancer cell lines 22Rv1 and DU145 to study the effect of ZEB1 modulation on docetaxel resistance and its possible mechanisms. Docetaxel 107-116 zinc finger E-box binding homeobox 1 Homo sapiens 88-92 30880686-6 2019 The results showed that ZEB1 overexpression conferred to 22Rv1 cell resistance to docetaxel while its silencing made DU145 cells more sensitive to it. Docetaxel 82-91 zinc finger E-box binding homeobox 1 Homo sapiens 24-28 30880686-9 2019 MRP4 inhibition, using MK571, resensitized cells with ZEB1 overexpression to docetaxel treatment. Docetaxel 77-86 zinc finger E-box binding homeobox 1 Homo sapiens 54-58 30880686-10 2019 In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression. Docetaxel 119-128 zinc finger E-box binding homeobox 1 Homo sapiens 27-31 30880686-12 2019 Our results showed that modulation of MRP4 could be a mediator of ZEB1-related resistance to docetaxel in prostate cancer, making it a possible marker for chemotherapy response in patients who do not express MDR1. Docetaxel 93-102 zinc finger E-box binding homeobox 1 Homo sapiens 66-70 29102917-0 2018 miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Docetaxel 28-37 zinc finger E-box binding homeobox 1 Homo sapiens 144-148 30771618-10 2019 E2F transcription factor 3 (E2F3) and zinc-finger E-box binding homeobox 1 (ZEB1) were two targets of miR-200b and mediated the function of MALAT1 in DTX-resistant LUAD cells. Docetaxel 150-153 zinc finger E-box binding homeobox 1 Homo sapiens 38-74 30771618-10 2019 E2F transcription factor 3 (E2F3) and zinc-finger E-box binding homeobox 1 (ZEB1) were two targets of miR-200b and mediated the function of MALAT1 in DTX-resistant LUAD cells. Docetaxel 150-153 zinc finger E-box binding homeobox 1 Homo sapiens 76-80 29102917-8 2018 Rescue experiments presented that ZEB1 overexpression abolished the effects of miR-27b or miR-34a overexpression on docetaxel sensitivity and EMT in docetaxel-resistant PCa cells. Docetaxel 149-158 zinc finger E-box binding homeobox 1 Homo sapiens 34-38 29102917-10 2018 In summary, miR-27b and miR-34a overexpression enhanced docetaxel sensitivity of PCa partly through inhibiting EMT by targeting ZEB1, providing new insights into the molecular mechanism of miR-27b and miR-34a in modulating docetaxel resistance and potential therapy targets in advanced PCa. Docetaxel 56-65 zinc finger E-box binding homeobox 1 Homo sapiens 128-132 29102917-10 2018 In summary, miR-27b and miR-34a overexpression enhanced docetaxel sensitivity of PCa partly through inhibiting EMT by targeting ZEB1, providing new insights into the molecular mechanism of miR-27b and miR-34a in modulating docetaxel resistance and potential therapy targets in advanced PCa. Docetaxel 223-232 zinc finger E-box binding homeobox 1 Homo sapiens 128-132 29102917-7 2018 Loss-of-function analysis disclosed that ZEB1 knockdown enhanced docetaxel sensitivity and suppressed EMT in docetaxel-resistant PCa cells. Docetaxel 65-74 zinc finger E-box binding homeobox 1 Homo sapiens 41-45 29102917-7 2018 Loss-of-function analysis disclosed that ZEB1 knockdown enhanced docetaxel sensitivity and suppressed EMT in docetaxel-resistant PCa cells. Docetaxel 109-118 zinc finger E-box binding homeobox 1 Homo sapiens 41-45 29102917-8 2018 Rescue experiments presented that ZEB1 overexpression abolished the effects of miR-27b or miR-34a overexpression on docetaxel sensitivity and EMT in docetaxel-resistant PCa cells. Docetaxel 116-125 zinc finger E-box binding homeobox 1 Homo sapiens 34-38 28133913-0 2017 The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer. Docetaxel 81-90 zinc finger E-box binding homeobox 1 Homo sapiens 54-58 28133913-3 2017 This study characterised EMT in docetaxel-resistant sublines through increased invasion, MMP-1 production and ZEB1 and ZEB2 expression. Docetaxel 32-41 zinc finger E-box binding homeobox 1 Homo sapiens 110-114 28133913-5 2017 siRNA manipulation of ZEB1 and ZEB2 in PC-3 and DU145 docetaxel-resistant sublines identified ZEB1, through its transcriptional repression of E-cadherin, to be a driver of both EMT and docetaxel resistance. Docetaxel 54-63 zinc finger E-box binding homeobox 1 Homo sapiens 22-26 28133913-5 2017 siRNA manipulation of ZEB1 and ZEB2 in PC-3 and DU145 docetaxel-resistant sublines identified ZEB1, through its transcriptional repression of E-cadherin, to be a driver of both EMT and docetaxel resistance. Docetaxel 54-63 zinc finger E-box binding homeobox 1 Homo sapiens 94-98 28133913-5 2017 siRNA manipulation of ZEB1 and ZEB2 in PC-3 and DU145 docetaxel-resistant sublines identified ZEB1, through its transcriptional repression of E-cadherin, to be a driver of both EMT and docetaxel resistance. Docetaxel 185-194 zinc finger E-box binding homeobox 1 Homo sapiens 22-26 28133913-5 2017 siRNA manipulation of ZEB1 and ZEB2 in PC-3 and DU145 docetaxel-resistant sublines identified ZEB1, through its transcriptional repression of E-cadherin, to be a driver of both EMT and docetaxel resistance. Docetaxel 185-194 zinc finger E-box binding homeobox 1 Homo sapiens 94-98 28133913-6 2017 The clinical relevance of ZEB1 was also determined through immunohistochemical tissue microarray assessment, revealing significantly increased ZEB1 expression in prostate tumours following docetaxel treatment. Docetaxel 189-198 zinc finger E-box binding homeobox 1 Homo sapiens 26-30 28133913-6 2017 The clinical relevance of ZEB1 was also determined through immunohistochemical tissue microarray assessment, revealing significantly increased ZEB1 expression in prostate tumours following docetaxel treatment. Docetaxel 189-198 zinc finger E-box binding homeobox 1 Homo sapiens 143-147 28133913-7 2017 This study presents evidence for a role of ZEB1, through its transcriptional repression of E-cadherin to be a driver of both EMT and docetaxel resistance in docetaxel-resistant prostate cancer. Docetaxel 133-142 zinc finger E-box binding homeobox 1 Homo sapiens 43-47 28133913-7 2017 This study presents evidence for a role of ZEB1, through its transcriptional repression of E-cadherin to be a driver of both EMT and docetaxel resistance in docetaxel-resistant prostate cancer. Docetaxel 157-166 zinc finger E-box binding homeobox 1 Homo sapiens 43-47 24659820-12 2014 ZEB1 siRNA transfection reverted docetaxel resistance and reduced CD44 expression in DU-145R and PC-3R. Docetaxel 33-42 zinc finger E-box binding homeobox 1 Homo sapiens 0-4 23255418-0 2013 Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. Docetaxel 55-64 zinc finger E-box binding homeobox 1 Homo sapiens 14-18 23255418-8 2013 Furthermore, inhibition of ZEB1 significantly enhanced the chemosensitivity of SPC-A1/DTX cells to docetaxel in vitro and in vivo and ectopic expression of ZEB1 increased the chemoresistance of SPC-A1 cells to docetaxel. Docetaxel 99-108 zinc finger E-box binding homeobox 1 Homo sapiens 27-31 23255418-8 2013 Furthermore, inhibition of ZEB1 significantly enhanced the chemosensitivity of SPC-A1/DTX cells to docetaxel in vitro and in vivo and ectopic expression of ZEB1 increased the chemoresistance of SPC-A1 cells to docetaxel. Docetaxel 210-219 zinc finger E-box binding homeobox 1 Homo sapiens 27-31 23255418-8 2013 Furthermore, inhibition of ZEB1 significantly enhanced the chemosensitivity of SPC-A1/DTX cells to docetaxel in vitro and in vivo and ectopic expression of ZEB1 increased the chemoresistance of SPC-A1 cells to docetaxel. Docetaxel 210-219 zinc finger E-box binding homeobox 1 Homo sapiens 156-160